The association between endostatin and kidney disease and mortality in patients with type 2 diabetes

Diabetes and Metabolism

Volumn 42, Issue 5, 2016, Pages 351-357

  Carlsson, A C ^a,b   Ostgren C J ^c   Lanne T ^c   Larsson, A ^b   Nystrom, F H ^c   Arnlov J ^b,d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c LINKÖPING UNIVERSITY   (Sweden)

^d DALARNA UNIVERSITY   (Sweden)

Author keywords

Albumin to creatinine ratio; Angiogenesis; Chronic kidney disease; Community; Extracellular matrix remodeling; NIDDM

Indexed keywords

ALBUMIN; CREATININE; ENDOSTATIN;

ADULT; ARTICLE; COHORT ANALYSIS; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MORTALITY; MORTALITY RISK; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PROTEIN FUNCTION; RISK ASSESSMENT; BLOOD; COMPLICATION; DIABETES MELLITUS, TYPE 2; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC;

DIABETES MELLITUS, TYPE 2; ENDOSTATINS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC;

EID: 84962874739     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2016.03.006     Document Type: Article

References (42)

1. [1] Haslam, D.W., James, W.P., Obesity. Lancet 366 (2005), 1197–1209.
2. [2] Wandell, P.E., Carlsson, A.C., Gender differences and time trends in incidence and prevalence of type 2 diabetes in Sweden – a model explaining the diabetes epidemic worldwide today?. Diabetes Res Clin Pract 106 (2014), e90–e92.
3. [3] Saarela, J., Ylikarppa, R., Rehn, M., Purmonen, S., Pihlajaniemi, T., Complete primary structure of two variant forms of human type XVIII collagen and tissue-specific differences in the expression of the corresponding transcripts. Matrix Biol 16 (1998), 319–328.
4. [4] Tomono, Y., Naito, I., Ando, K., Yonezawa, T., Sado, Y., Hirakawa, S., et al. Epitope-defined monoclonal antibodies against multiplexin collagens demonstrate that type XV and XVIII collagens are expressed in specialized basement membranes. Cell Struct Funct 27 (2002), 9–20.
5. [5] Herget-Rosenthal, S., van Wijk, J.A., Brocker-Preuss, M., Bokenkamp, A., Increased urinary cystatin C reflects structural and functional renal tubular impairment independent of glomerular filtration rate. Clin Biochem 40 (2007), 946–951.
6. [6] Hamano, Y., Okude, T., Shirai, R., Sato, I., Kimura, R., Ogawa, M., et al. Lack of collagen XVIII/endostatin exacerbates immune-mediated glomerulonephritis. J Am Soc Nephrol 21 (2010), 1445–1455.
7. [7] Ichinose, K., Maeshima, Y., Yamamoto, Y., Kitayama, H., Takazawa, Y., Hirokoshi, K., et al. Antiangiogenic endostatin peptide ameliorates renal alterations in the early stage of a type 1 diabetic nephropathy model. Diabetes 54 (2005), 2891–2903.
8. [8] Bai, X., Li, X., Tian, J., Zhou, Z., Antiangiogenic treatment diminishes renal injury and dysfunction via regulation of local AKT in early experimental diabetes. PLOS ONE, 9, 2014, e96117.
9. [9] Lin, C.H., Chen, J., Ziman, B., Marshall, S., Maizel, J., Goligorsky, M.S., Endostatin and kidney fibrosis in aging: a case for antagonistic pleiotropy?. Am J Physiol Heart Circ Physiol 306 (2014), H1692–H1699.
10. [10] Carlsson, A.C., Ruge, T., Sundstrom, J., Ingelsson, E., Larsson, A., Lind, L., et al. Association between circulating endostatin, hypertension duration, and hypertensive target-organ damage. Hypertension 62 (2013), 1146–1151.
11. [11] Ruge, T., Carlsson, A.C., Larsson, T.E., Carrero, J.J., Larsson, A., Lind, L., et al. Endostatin level is associated with kidney injury in the elderly: findings from two community-based cohorts. Am J Nephrol 40 (2014), 417–424.
12. [12] Arnlov, J., Ruge, T., Ingelsson, E., Larsson, A., Sundstrom, J., Lind, L., Serum endostatin and risk of mortality in the elderly: findings from 2 community-based cohorts. Arterioscler Thromb Vasc Biol 33:November (11) (2013), 2689–2695.
13. [13] Wagener, G., Jan, M., Kim, M., Mori, K., Barasch, J.M., Sladen, R.N., et al. Association between increases in urinary neutrophil gelatinase-associated lipocalin and acute renal dysfunction after adult cardiac surgery. Anesthesiology 105 (2006), 485–491.
14. [14] Levey, A.S., Stevens, L.A., Schmid, C.H., Zhang, Y.L., Castro, A.F. 3rd, Feldman, H.I., et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 150 (2009), 604–612.
15. [15] Bottai, M., Zhang, J., Laplace regression with censored data. Biom J 52 (2010), 487–503.
16. [16] Harrell, F.E. Jr., Lee, K.L., Mark, D.B., Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15 (1996), 361–387.
17. [17] Chen, J., Hamm, L.L., Kleinpeter, M.A., Husserl, F., Khan, I.E., Chen, C.S., et al. Elevated plasma levels of endostatin are associated with chronic kidney disease. Am J Nephrol 35 (2012), 335–340.
18. [18] Futrakul, N., Butthep, P., Laohareungpanya, N., Chaisuriya, P., Ratanabanangkoon, K., A defective angiogenesis in chronic kidney disease. Ren Fail 30 (2008), 215–217.
19. [19] Watorek, E., Paprocka, M., Dus, D., Kopec, W., Klinger, M., Endostatin and vascular endothelial growth factor: potential regulators of endothelial progenitor cell number in chronic kidney disease. Pol Arch Med Wewn 121 (2011), 296–301.
20. [20] Bolignano, D., Coppolino, G., Lacquaniti, A., Buemi, M., From kidney to cardiovascular diseases: NGAL as a biomarker beyond the confines of nephrology. Eur J Clin Invest 40 (2010), 273–276.
21. [21] Yamaguchi, N., Anand-Apte, B., Lee, M., Sasaki, T., Fukai, N., Shapiro, R., et al. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J 18 (1999), 4414–4423.
22. [22] Rong, B., Yang, S., Li, W., Zhang, W., Ming, Z., Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer. World J Surg Oncol, 10, 2012, 170.
23. [23] Li, W., Yu, Y., He, H., Chen, J., Zhang, D., Urinary kidney injury molecule-1 as an early indicator to predict contrast-induced acute kidney injury in patients with diabetes mellitus undergoing percutaneous coronary intervention. Biomed Rep 3 (2015), 509–512.
24. [24] O'Riordan, E., Mendelev, N., Patschan, S., Patschan, D., Eskander, J., Cohen-Gould, L., et al., Chronic, N.O.S., inhibition actuates endothelial–mesenchymal transformation. Am J Physiol Heart Circ Physiol 292 (2007), H285–H294.
25. [25] Rudnicki, M., Perco, P., Enrich, J., Eder, S., Heininger, D., Bernthaler, A., et al. Hypoxia response and VEGF-A expression in human proximal tubular epithelial cells in stable and progressive renal disease. Lab Invest 89 (2009), 337–346.
26. [26] Lerman, L.O., Chade, A.R., Angiogenesis in the kidney: a new therapeutic target?. Curr Opin Nephrol Hypertens 18 (2009), 160–165.
27. [27] Tanaka, T., Nangaku, M., Angiogenesis and hypoxia in the kidney. Nat Rev Nephrol 9 (2013), 211–222.
28. [28] Stoessel, A., Paliege, A., Theilig, F., Addabbo, F., Ratliff, B., Waschke, J., et al. Indolent course of tubulointerstitial disease in a mouse model of subpressor, low-dose nitric oxide synthase inhibition. Am J Physiol Renal Physiol 295 (2008), F717–F725.
29. [29] Dihazi, H., Dihazi, G.H., Bibi, A., Eltoweissy, M., Mueller, C.A., Asif, A.R., et al. Secretion of ERP57 is important for extracellular matrix accumulation and progression of renal fibrosis, and is an early sign of disease onset. J Cell Sci 126 (2013), 3649–3663.
30. [30] Komorowski, J., Jankiewicz-Wika, J., Kolomecki, K., Cywinski, J., Piestrzeniewicz, K., Swietoslawski, J., et al. Systemic blood osteopontin, endostatin, and E-selectin concentrations after vertical banding surgery in severely obese adults. Cytokine 55 (2011), 56–61.
31. [31] Silha, J.V., Krsek, M., Sucharda, P., Murphy, L.J., Angiogenic factors are elevated in overweight and obese individuals. Int J Obes (Lond) 29 (2005), 1308–1314.
32. [32] Yang, X.X., Hu, Z.P., Chan, E., Duan, W., Zhou, S., Pharmacokinetics of recombinant human endostatin in rats. Curr Drug Metab 7 (2006), 565–576.
33. [33] Mimura, I., Nangaku, M., The suffocating kidney: tubulointerstitial hypoxia in end-stage renal disease. Nat Rev Nephrol 6 (2010), 667–678.
34. [34] Arenillas, J.F., Alvarez-Sabin, J., Montaner, J., Rosell, A., Molina, C.A., Rovira, A., et al. Angiogenesis in symptomatic intracranial atherosclerosis: predominance of the inhibitor endostatin is related to a greater extent and risk of recurrence. Stroke 36 (2005), 92–97.
35. [35] Dziankowska-Bartkowiak, B., Waszczykowska, E., Zalewska, A., Sysa-Jedrzejowska, A., Correlation of endostatin and tissue inhibitor of metalloproteinases 2 (TIMP2) serum levels with cardiovascular involvement in systemic sclerosis patients. Mediators Inflamm 2005 (2005), 144–149.
36. [36] Mitsuma, W., Kodama, M., Hanawa, H., Ito, M., Ramadan, M.M., Hirono, S., et al. Serum endostatin in the coronary circulation of patients with coronary heart disease and its relation to coronary collateral formation. Am J Cardiol 99 (2007), 494–498.
37. [37] Panchal, V.R., Rehman, J., Nguyen, A.T., Brown, J.W., Turrentine, M.W., Mahomed, Y., et al. Reduced pericardial levels of endostatin correlate with collateral development in patients with ischemic heart disease. J Am Coll Cardiol 43 (2004), 1383–1387.
38. [38] Ramazani, M., Lundin, C., Sund, M., Increased circulating levels of basement-membrane components in patients with abdominal aortic aneurysms – a pilot study. Eur J Vasc Endovasc Surg 42 (2011), 484–487.
39. [39] Seko, Y., Fukuda, S., Nagai, R., Serum levels of endostatin, vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in patients with acute myocardial infarction undergoing early reperfusion therapy. Clin Sci (Lond) 106 (2004), 439–442.
40. [40] Moulton, K.S., Heller, E., Konerding, M.A., Flynn, E., Palinski, W., Folkman, J., Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 99 (1999), 1726–1732.
41. [41] Moulton, K.S., Olsen, B.R., Sonn, S., Fukai, N., Zurakowski, D., Zeng, X., Loss of collagen XVIII enhances neovascularization and vascular permeability in atherosclerosis. Circulation 110 (2004), 1330–1336.
42. [42] Zeng, X., Chen, J., Miller, Y.I., Javaherian, K., Moulton, K.S., Endostatin binds biglycan and LDL and interferes with LDL retention to the subendothelial matrix during atherosclerosis. J Lipid Res 46 (2005), 1849–1859.